argenx NV ADR (ARGX)vsHCW Biologics Inc (HCWB)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
HCWB
HCW Biologics Inc
$1.79
-13.53%
HEALTHCARE · Cap: $11.67M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 71841% more annual revenue ($4.74B vs $6.59M). ARGX leads profitability with a 31.4% profit margin vs -34.7%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
HCWB
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Intrinsic value data unavailable for HCWB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 49.4%
Revenue surging 129081.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : HCWB
The strongest argument for HCWB centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 129081.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while HCWB is a hypergrowth play — different risk/reward profiles.
HCWB carries more volatility with a beta of 1.14 — expect wider price swings.
HCWB is growing revenue faster at 129081.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 43/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is a pioneering biotechnology firm focused on advancing immunotherapies and vaccine technologies to tackle critical health issues like cancer and infectious diseases. By utilizing proprietary platforms designed to optimize immune response, the company is developing a promising pipeline of clinical candidates that aim to revolutionize patient treatment. With strategic partnerships and a dedication to fulfilling unmet medical needs, HCW Biologics stands at the forefront of the biotechnology industry, representing a compelling investment opportunity amid the sector's growth.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?